We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
BTG | LSE:BGC | London | Ordinary Share | GB0001001592 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 387.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:1003S BTG PLC 14 November 2003 14 November 2003 - for immediate release BTG plc: Statement on Varisolve(R) US Phase II safety study BTG plc (LSE: BGC), the global technology commercialisation company, today announced that it has been informed verbally by the US Food & Drug Administration (FDA) of a decision to place on clinical hold a Phase II safety study of Varisolve(R), a new treatment for varicose veins being developed by Provensis, BTG's subsidiary. FDA has indicated it will write to Provensis describing the reasons for placing the study on clinical hold. BTG will make a further announcement after receiving the FDA's letter and assessing the impact on the further clinical development of Varisolve(R). Ends For further information contact: BTG Andy Burrows, Director of Investor Relations +44 (0)20 7575 1741 07990 530605 This information is provided by RNS The company news service from the London Stock Exchange END RESNKQKNPBDDQDD
1 Year BTG Chart |
1 Month BTG Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions